Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 08, 2021, titled "Glenmark s interim data from PMS Study on Favipiravir (FabiFlu��) supports its safety and effectiveness in real world settings with no new safety signals or concerns in Covid‐19 patients".